In partnership with sanofi pasteur Crucell is developing a PER.C6^®-based influenza vaccine. PER.C6^® cells are highly susceptible to influenza viruses, thereby making the production of large amounts of influenza virus vaccine feasible. For further information on this program please refer to our R&D section of the website or download the following documents.

• About Influenza (PDF)
• Developing an Influenza Vaccine (PDF)

05 April 2007: Crucell broadens pandemic preparedness with grant awarded to develop H5N1 Influenza vaccine

03 April 2007: Crucell secures important patent covering influenza vaccine production

22 March 2007: Crucell announces influenza alliance with ADImmune Corporation

31 May 2006: Crucell Announces Large Human Clinical Trial with Avian Influenza Vaccine

13 Oct. 2005: Crucell Updates Progress in Scale-up of Cell-culture-based Influenza Vaccine Programs

1 April 2005: Crucell's Cell-Culture Technology to Be Part of Major U.S. Government Influenza Pandemic Vaccine Program

14 Jan. 2005: Crucell Joins Influenza Vaccine Supply (IVS) International Task Force

7 Jan. 2004: Aventis and Crucell Announce Strategic Agreement to Develop and Commercialize Novel Influenza Vaccines

27 Jan. 2003: Crucell and Aventis Pasteur Sign License Agreement for Manufacturing Viral Vaccines

Publications related to Crucell’s influenza vaccine program are listed below. Please click on any of these to access the abstracts of the articles. For more Crucell scientific papers please use search word ‘Crucell’ at PubMed, http://www.ncbi.nlm.nih.gov./entrez/query.fcgi.

Kapteyn, JC et al. Haemagglutinin quantification and identification of influenza A&B strains propagated in PER.C6® cells: a novel RP-HPLC method. Vaccine. 2006. 24(16), 3137-3144.

Visit Useful Links